- Abstract:
-
Backround: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the MAPK pathway is activated in most melanoma, including BRAF-wt. We assessed whether inhibiting this pathway by adding kinase inhibitors tr...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's Version
- Files:
-
-
(pdf, 208.9KB)
-
- Publisher copy:
- 10.1093/annonc/mdy500
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Annals of Oncology Journal website
- Volume:
- 30
- Issue:
- 2
- Pages:
- 317–324
- Publication date:
- 2018-11-14
- Acceptance date:
- 2018-10-30
- DOI:
- EISSN:
-
1569-8041
- ISSN:
-
0923-7534
- Pubs id:
-
pubs:942833
- URN:
-
uri:aa8a31a4-139a-4f97-a8f6-792c7a7ffdba
- UUID:
-
uuid:aa8a31a4-139a-4f97-a8f6-792c7a7ffdba
- Local pid:
- pubs:942833
- Copyright holder:
- Urbonas, et al
- Copyright date:
- 2018
- Notes:
-
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Journal article
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
GSK/Novartis
More from this funder
National Cancer
Research Network
More from this funder
University of Oxford
More from this funder
Bibliographic Details
Terms of use
If you are the owner of this record, you can report an update to it here: Report update to this record